{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T01:51:21Z","timestamp":1783734681417,"version":"3.55.0"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T00:00:00Z","timestamp":1566950400000},"content-version":"am","delay-in-days":331,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K02 DA039229"],"award-info":[{"award-number":["K02 DA039229"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["K23 AA023845"],"award-info":[{"award-number":["K23 AA023845"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["I01CX001136-01"],"award-info":[{"award-number":["I01CX001136-01"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006379","name":"Office of Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006379","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.cct.2018.08.009","type":"journal-article","created":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T23:41:43Z","timestamp":1535067703000},"page":"8-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Doxazosin for the treatment of co-occurring PTSD and alcohol use disorder: Design and methodology of a randomized controlled trial in military veterans"],"prefix":"10.1016","volume":"73","author":[{"given":"Sudie E.","family":"Back","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julianne C.","family":"Flanagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Augur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan L.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Young-McCaughan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Shirley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisling","family":"Henschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane E.","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett T.","family":"Litz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison K.","family":"Hancock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Roache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Mintz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S.","family":"Wachen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence M.","family":"Keane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen T.","family":"Brady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.cct.2018.08.009_bb0005","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1159\/000362243","article-title":"Comparing the effect of prazosin and hydroxyzine on sleep quality in patients suffering from posttraumatic stress disorder","volume":"69","author":"Ahmadpanah","year":"2014","journal-title":"Neuropsychobiology"},{"issue":"1","key":"10.1016\/j.cct.2018.08.009_bb0010","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1530-0277.1995.tb01475.x","article-title":"The Obsessive Compulsive Drinking Scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior","volume":"19","author":"Anton","year":"1995","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.cct.2018.08.009_bb0015","unstructured":"Barnes, J. B., Presseau, C., Jordan, A. H., Kline, N. K., S, Y. M., Peterson, A. L.,\u2026, and The Consortium to Alleviate PTSD. (under review). Common data elements for military-related PTSD research applied in the consortium to alleviate PTSD."},{"issue":"8","key":"10.1016\/j.cct.2018.08.009_bb0020","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1111\/acer.12496","article-title":"Topiramate treatment of alcohol use disorder in veterans with posttraumatic stress disorder: a randomized controlled pilot trial","volume":"38","author":"Batki","year":"2014","journal-title":"Alcohol. Clin. Exp. Res."},{"issue":"10","key":"10.1016\/j.cct.2018.08.009_bb0025","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1097\/01.ALC.0000090144.99832.19","article-title":"Treatment of Alcohol Abuse: an Evidence-based Review","volume":"27","author":"Berglund","year":"2003","journal-title":"Alcohol. Clin. Exp. Res."},{"issue":"3","key":"10.1016\/j.cct.2018.08.009_bb0030","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.drugalcdep.2013.04.016","article-title":"Comorbidity of posttraumatic stress disorder with alcohol dependence among US adults: results from National epidemiological survey on alcohol and related conditions","volume":"132","author":"Blanco","year":"2013","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.cct.2018.08.009_bb0035","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1037\/pas0000254","article-title":"Psychometric properties of the PTSD Checklist for Diagnostic and Statistical Manual of Mental Disorders\u2013Fifth Edition (PCL-5) in veterans","volume":"28","author":"Bovin","year":"2016","journal-title":"Psychol. Assess."},{"issue":"14","key":"10.1016\/j.cct.2018.08.009_bb0040","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1001\/jama.283.14.1837","article-title":"Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial","volume":"283","author":"Brady","year":"2000","journal-title":"J. Am. Med. Assoc."},{"issue":"3","key":"10.1016\/j.cct.2018.08.009_bb0045","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/01.ALC.0000156129.98265.57","article-title":"Sertraline in the treatment of co-occurring alcohol dependence and posttraumatic stress disorder","volume":"29","author":"Brady","year":"2005","journal-title":"Alcoholism"},{"issue":"3","key":"10.1016\/j.cct.2018.08.009_bb0050","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jsat.2012.07.013","article-title":"Development and initial evaluation of the Brief Addiction Monitor (BAM)","volume":"44","author":"Cacciola","year":"2013","journal-title":"J. Subst. Abus. Treat."},{"issue":"4","key":"10.1016\/j.cct.2018.08.009_bb0055","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1177\/0269881103174017","article-title":"Does acamprosate improve reduction of drinking as well as aiding abstinence?","volume":"17","author":"Chick","year":"2003","journal-title":"J. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.cct.2018.08.009_bb0060","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1001\/archpsyc.58.5.485","article-title":"Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder","volume":"58","author":"Davidson","year":"2001","journal-title":"Arch. Gen. Psychiatry"},{"issue":"1","key":"10.1016\/j.cct.2018.08.009_bb0065","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/JCP.0b013e3181c827ae","article-title":"Doxazosin treatment for posttraumatic stress disorder","volume":"30","author":"De Jong","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.cct.2018.08.009_bb0070","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1001\/jama.2013.8268","article-title":"Concurrent naltrexone and prolonged exposure therapy for patients with comorbid alcohol dependence and PTSD: a randomized clinical trial","volume":"310","author":"Foa","year":"2013","journal-title":"J. Am. Med. Assoc."},{"issue":"2","key":"10.1016\/j.cct.2018.08.009_bb0075","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1530-0277.2011.01628.x","article-title":"Prazosin effects on stress-and cue-induced craving and stress response in alcohol-dependent individuals: preliminary findings","volume":"36","author":"Fox","year":"2012","journal-title":"Alcohol. Clin. Exp. Res."},{"issue":"3","key":"10.1016\/j.cct.2018.08.009_bb0080","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1006\/nimg.1997.0291","article-title":"Psychophysiological and modulatory interactions in neuroimaging","volume":"6","author":"Friston","year":"1997","journal-title":"NeuroImage"},{"issue":"2","key":"10.1016\/j.cct.2018.08.009_bb0085","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2165\/00003495-199549020-00011","article-title":"Doxazosin","volume":"49","author":"Fulton","year":"1995","journal-title":"Drugs"},{"key":"10.1016\/j.cct.2018.08.009_bb0090","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jpsychores.2011.11.010","article-title":"Placebo-controlled comparison of prazosin and cognitive-behavioral treatments for sleep disturbances in US military veterans","volume":"72","author":"Germain","year":"2012","journal-title":"J. Psychosom. Res."},{"issue":"8","key":"10.1016\/j.cct.2018.08.009_bb0095","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1001\/jamapsychiatry.2015.0584","article-title":"Epidemiology of DSM-5 alcohol use disorder: results from the national epidemiologic survey on alcohol and related conditions III","volume":"72","author":"Grant","year":"2015","journal-title":"JAMA psychiatry"},{"key":"10.1016\/j.cct.2018.08.009_bb0100","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.drugalcdep.2017.03.016","article-title":"Higher pretreatment blood pressure is associated with greater alcohol drinking reduction in alcohol-dependent individuals treated with doxazosin","volume":"177","author":"Haass-Koffler","year":"2017","journal-title":"Drug Alcohol Dependence"},{"key":"10.1016\/j.cct.2018.08.009_bb0105","first-page":"1","article-title":"Noradrenergic targets for the treatment of alcohol use disorder","author":"Haass-Koffler","year":"2018","journal-title":"Psychopharmacology"},{"issue":"4","key":"10.1016\/j.cct.2018.08.009_bb0110","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1001\/archgenpsychiatry.2008.536","article-title":"Tracing the flow of knowledge: geographic variability in the diffusion of prazosin use for the treatment of posttraumatic stress disorder nationally in the Department of Veterans Affairs","volume":"66","author":"Harpaz-Rotem","year":"2009","journal-title":"Arch. Gen. Psychiatry"},{"issue":"1","key":"10.1016\/j.cct.2018.08.009_bb0115","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1176\/appi.ajp.2013.13091259","article-title":"Diffusion of prazosin treatment for PTSD","volume":"171","author":"Hermes","year":"2014","journal-title":"Am. J. Psychiatr."},{"issue":"6","key":"10.1016\/j.cct.2018.08.009_bb0120","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1017\/S1461145711001209","article-title":"Evidence-based pharmacotherapy of post-traumatic stress disorder (PTSD)","volume":"15","author":"Ipser","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.cct.2018.08.009_bb0125","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0269881110367448","article-title":"The role of central noradrenergic dysregulation in anxiety disorders: evidence from clinical studies","volume":"25","author":"Kalk","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.cct.2018.08.009_bb0130","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000475055","article-title":"Terazosin and doxazosin in normotensive men with symptomatic prostatism: a pilot study to determine the effect of dosing regimen on efficacy and safety","volume":"28","author":"Kaplan","year":"1995","journal-title":"Eur. Urol."},{"key":"10.1016\/j.cct.2018.08.009_bb0135","first-page":"1","article-title":"VA Cooperative Study# 334: Summary of findings on the psychophysiological assessment of PTSD","volume":"9","author":"Keane","year":"1998","journal-title":"PTSD Res. Quarterly"},{"issue":"4","key":"10.1016\/j.cct.2018.08.009_bb0140","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/adb.12275","article-title":"Role of the \u03b11 blocker doxazosin in alcoholism: a proof-of-concept randomized controlled trial","volume":"21","author":"Kenna","year":"2016","journal-title":"Addict. Biol."},{"issue":"24","key":"10.1016\/j.cct.2018.08.009_bb0145","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1056\/NEJMsa043266","article-title":"Prevalence and treatment of mental disorders, 1990 to 2003","volume":"352","author":"Kessler","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.cct.2018.08.009_bb0150","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/sj.pcan.4500220","article-title":"Morning vs evening dosing with doxazosin in benign prostatic hyperplasia: efficacy and safety","volume":"1","author":"Kirby","year":"1998","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.cct.2018.08.009_bb0155","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1038\/sj.npp.1301548","article-title":"Drugs of abuse specifically sensitize noradrenergic and serotonergic neurons via a non-dopaminergic mechanism","volume":"33","author":"Lanteri","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.cct.2018.08.009_bb0160","article-title":"Doxazosin for Alcohol Dependence: a pilot Double-blind Placebo-controlled Trial","volume":"39","author":"Le","year":"2015","journal-title":"Alcoholism"},{"issue":"2","key":"10.1016\/j.cct.2018.08.009_bb0165","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1360-0443.2012.04054.x","article-title":"Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?","volume":"108","author":"Maisel","year":"2013","journal-title":"Addiction"},{"key":"10.1016\/j.cct.2018.08.009_bb0170","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/archgenpsychiatry.2009.109","article-title":"Association of time since deployment, combat intensity, and posttraumatic stress symptoms with neuropsychological outcomes following Iraq war deployment","volume":"66","author":"Marx","year":"2009","journal-title":"Arch. Gen. Psychiatry"},{"issue":"3","key":"10.1016\/j.cct.2018.08.009_bb0175","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0740-5472(92)90062-S","article-title":"The fifth edition of the Addiction Severity Index","volume":"9","author":"McLellan","year":"1992","journal-title":"J. Subst. Abus. Treat."},{"issue":"8","key":"10.1016\/j.cct.2018.08.009_bb0180","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cpr.2009.09.002","article-title":"Military-related PTSD and intimate relationships: from description to theory-driven research and intervention development","volume":"29","author":"Monson","year":"2009","journal-title":"Clin. Psychol. Rev."},{"issue":"2","key":"10.1016\/j.cct.2018.08.009_bb0185","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1530-0277.2012.01884.x","article-title":"The \u03b11-Adrenergic Receptor Antagonist, Doxazosin, Reduces Alcohol Drinking in Alcohol-Preferring (P) Rats","volume":"37","author":"O'Neil","year":"2013","journal-title":"Alcohol. Clin. Exp. Res."},{"issue":"5","key":"10.1016\/j.cct.2018.08.009_bb0190","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1093\/scan\/nss055","article-title":"Tools of the trade: psychophysiological interactions and functional connectivity","volume":"7","author":"O'Reilly","year":"2012","journal-title":"Soc. Cogn. Affect. Neurosci."},{"issue":"2","key":"10.1016\/j.cct.2018.08.009_bb0195","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1037\/0022-006X.71.2.410","article-title":"PTSD treatment and 5-year remission among patients with substance use and posttraumatic stress disorders","volume":"71","author":"Ouimette","year":"2003","journal-title":"J. Consult. Clin. Psychol."},{"key":"10.1016\/j.cct.2018.08.009_bb0200","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/alcalc\/agg055","article-title":"Changes in plasma noradrenaline and serotonin levels and craving during alcohol withdrawal","volume":"38","author":"Patkar","year":"2003","journal-title":"Alcohol"},{"issue":"1","key":"10.1016\/j.cct.2018.08.009_bb0205","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/acer.12926","article-title":"Prazosin for veterans with Posttraumatic stress disorder and comorbid alcohol dependence: a clinical trial","volume":"40","author":"Petrakis","year":"2016","journal-title":"Alcohol. Clin. Exp. Res."},{"issue":"4","key":"10.1016\/j.cct.2018.08.009_bb0210","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/npp.2011.283","article-title":"Noradrenergic vs serotonergic antidepressant with or without naltrexone for veterans with PTSD and comorbid alcohol dependence","volume":"37","author":"Petrakis","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.cct.2018.08.009_bb0215","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1521-0391.2011.00126.x","article-title":"Substance Use Comorbidity among Veterans with Posttraumatic stress Disorder and Other Psychiatric Illness","volume":"20","author":"Petrakis","year":"2011","journal-title":"Am. J. Addict."},{"issue":"2","key":"10.1016\/j.cct.2018.08.009_bb0220","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/acer.13297","article-title":"Posttraumatic stress disorder and alcohol use disorder: a critical review of pharmacologic treatments","volume":"41","author":"Petrakis","year":"2017","journal-title":"Alcohol. Clin. Exp. Res."},{"issue":"8","key":"10.1016\/j.cct.2018.08.009_bb0225","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/da.20574","article-title":"Subsyndromal posttraumatic stress disorder is associated with health and psychosocial difficulties in veterans of Operations Enduring Freedom and Iraqi Freedom","volume":"26","author":"Pietrzak","year":"2009","journal-title":"Depression Anxiety"},{"issue":"3","key":"10.1016\/j.cct.2018.08.009_bb0230","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.janxdis.2010.11.010","article-title":"Prevalence and Axis I comorbidity of full and partial posttraumatic stress disorder in the United States: results from Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions","volume":"25","author":"Pietrzak","year":"2011","journal-title":"J. Anxiety Disord."},{"issue":"3","key":"10.1016\/j.cct.2018.08.009_bb0235","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.janxdis.2010.11.010","article-title":"Prevalence and Axis I comorbidity of full and partial posttraumatic stress disorder in the United States: results from Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions","volume":"25","author":"Pietrzak","year":"2011","journal-title":"J. Anxiety Disord."},{"issue":"10","key":"10.1016\/j.cct.2018.08.009_bb0240","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.biopsych.2016.03.2108","article-title":"Higher pretreatment blood pressure is associated with greater posttraumatic stress disorder symptom reduction in soldiers treated with prazosin","volume":"80","author":"Raskind","year":"2016","journal-title":"Biol. Psychiatry"},{"issue":"6","key":"10.1016\/j.cct.2018.08.009_bb0245","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1507598","article-title":"Trial of prazosin for post-traumatic stress disorder in military veterans","volume":"378","author":"Raskind","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.cct.2018.08.009_bb0250","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.biopsych.2006.06.032","article-title":"A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder","volume":"61","author":"Raskind","year":"2007","journal-title":"Biol. Psychiatry"},{"issue":"8","key":"10.1016\/j.cct.2018.08.009_bb0255","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.biopsych.2006.06.032","article-title":"A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder","volume":"61","author":"Raskind","year":"2007","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.cct.2018.08.009_bb0260","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1176\/appi.ajp.160.2.371","article-title":"Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study","volume":"160","author":"Raskind","year":"2003","journal-title":"Am. J. Psychiatr."},{"issue":"9","key":"10.1016\/j.cct.2018.08.009_bb0265","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1176\/appi.ajp.2013.12081133","article-title":"A trial of prazosin for combat trauma PTSD with nightmares in active-duty soldiers returned from Iraq and Afghanistan","volume":"170","author":"Raskind","year":"2013","journal-title":"Am. J. Psychiatr."},{"issue":"5","key":"10.1016\/j.cct.2018.08.009_bb0270","doi-asserted-by":"crossref","first-page":"e561","DOI":"10.4088\/JCP.14m09681","article-title":"Doxazosin XL reduces symptoms of posttraumatic stress disorder in veterans with PTSD: a pilot clinical trial","volume":"77","author":"Rodgman","year":"2016","journal-title":"The Journal of clinical psychiatry"},{"issue":"5","key":"10.1016\/j.cct.2018.08.009_bb0275","doi-asserted-by":"crossref","first-page":"e561","DOI":"10.4088\/JCP.14m09681","article-title":"Doxazosin XL reduces symptoms of posttraumatic stress disorder in veterans with PTSD: a pilot clinical trial","volume":"77","author":"Rodgman","year":"2016","journal-title":"The Journal of clinical psychiatry"},{"issue":"5","key":"10.1016\/j.cct.2018.08.009_bb0280","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1001\/archinte.167.5.476","article-title":"Bringing the war back home: Mental health disorders among 103 788 US veterans returning from Iraq and Afghanistan seen at Department of Veterans Affairs Facilities","volume":"167","author":"Seal","year":"2007","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.cct.2018.08.009_bb0285","first-page":"22","article-title":"The mini-international neuropsychiatric interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.cct.2018.08.009_bb0290","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.drugalcdep.2012.11.021","article-title":"The alpha-1 adrenergic antagonist doxazosin for treatment of cocaine dependence: a pilot study","volume":"131","author":"Shorter","year":"2013","journal-title":"Drug Alcohol Dependence"},{"issue":"5","key":"10.1016\/j.cct.2018.08.009_bb0295","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/acer.12703","article-title":"A pilot trial of prazosin, an alpha-1 adrenergic antagonist, for comorbid alcohol dependence and posttraumatic stress disorder","volume":"39","author":"Simpson","year":"2015","journal-title":"Alcohol. Clin. Exp. Res."},{"issue":"2","key":"10.1016\/j.cct.2018.08.009_bb0300","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1530-0277.2008.00807.x","article-title":"A pilot trial of the alpha-1 adrenergic antagonist, prazosin, for alcohol dependence","volume":"33","author":"Simpson","year":"2009","journal-title":"Alcohol. Clin. Exp. Res."},{"issue":"5","key":"10.1016\/j.cct.2018.08.009_bb0305","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/npp.2008.78","article-title":"Enhanced negative emotion and alcohol craving, and altered physiological responses following stress and cue exposure in alcohol dependent individuals","volume":"34","author":"Sinha","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.cct.2018.08.009_bb0310","series-title":"Timeline follow-back: A technique for assessing self-reported alcohol consumption","author":"Sobell","year":"1992"},{"issue":"2","key":"10.1016\/j.cct.2018.08.009_bb0315","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.addbeh.2013.08.014","article-title":"Pharmacological treatment of comorbid PTSD and substance use disorder: recent progress","volume":"39","author":"Sofuoglu","year":"2014","journal-title":"Addict. Behav."},{"issue":"1","key":"10.1016\/j.cct.2018.08.009_bb0320","first-page":"25","article-title":"Pharmacotherapy of posttraumatic stress disorder: a review of meta-analyses and treatment guidelines","volume":"14","author":"Stein","year":"2009","journal-title":"CNS Spectrums"},{"key":"10.1016\/j.cct.2018.08.009_bb0325","series-title":"Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings","author":"Abuse","year":"2013"},{"issue":"11","key":"10.1016\/j.cct.2018.08.009_bb0330","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/j.1360-0443.1989.tb00737.x","article-title":"Assessment of Alcohol Withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar)","volume":"84","author":"Sullivan","year":"1989","journal-title":"Br. J. Addict."},{"key":"10.1016\/j.cct.2018.08.009_bb0335","series-title":"Invisible Wounds of War. Summary and Recommendations for Addressing Psychological and Cognitive Injuries","author":"Tanielian","year":"2008"},{"issue":"6","key":"10.1016\/j.cct.2018.08.009_bb0340","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.biopsych.2007.07.001","article-title":"Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma posttraumatic stress disorder: a placebo-controlled study","volume":"63","author":"Taylor","year":"2008","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.cct.2018.08.009_bb0345","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jsat.2011.09.001","article-title":"Integrated treatment programs for individuals with concurrent substance use disorders and trauma experiences: a systematic review and meta-analysis","volume":"42","author":"Torchalla","year":"2012","journal-title":"J. Subst. Abus. Treat."},{"issue":"3","key":"10.1016\/j.cct.2018.08.009_bb0350","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.cpr.2012.01.004","article-title":"Psychological treatments for concurrent posttraumatic stress disorder and substance use disorder: a systematic review","volume":"32","author":"van Dam","year":"2012","journal-title":"Clin. Psychol. Rev."},{"key":"10.1016\/j.cct.2018.08.009_bb0355","series-title":"Paper Presented at the the 29th annual Meeting of the International Society for Traumatic Stress Studies Philadelphia","article-title":"The PTSD checklist for DSM-5 (PCL-5): development and initial psychometric analysis","author":"Weathers","year":"2013"},{"key":"10.1016\/j.cct.2018.08.009_bb0360","series-title":"Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)","author":"Weathers","year":"2013"},{"key":"10.1016\/j.cct.2018.08.009_bb0365","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1111\/j.1360-0443.2004.00884.x","article-title":"Adherence to pharmacotherapy in patients with alcohol and opioid dependence","volume":"99","author":"Weiss","year":"2004","journal-title":"Addiction"},{"key":"10.1016\/j.cct.2018.08.009_bb0370","doi-asserted-by":"crossref","DOI":"10.1097\/ADM.0000000000000413","article-title":"A randomized, placebo-controlled, clinical trial of prazosin for the treatment of alcohol use disorder","author":"Wilcox","year":"2018","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.cct.2018.08.009_bb0375","article-title":"Pharmacogenetics of dopamine B-hydroxylase in cocaine depenence therapy with doxazosin","author":"Zhang","year":"2018","journal-title":"Addict. Biol."},{"issue":"2","key":"10.1016\/j.cct.2018.08.009_bb0380","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/00004714-200204000-00013","article-title":"Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder","volume":"22","author":"Zohar","year":"2002","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.cct.2018.08.009_bb3361","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br. J. Psychiatry"}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714418303896?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714418303896?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:46:19Z","timestamp":1761554779000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714418303896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":77,"alternative-id":["S1551714418303896"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2018.08.009","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Doxazosin for the treatment of co-occurring PTSD and alcohol use disorder: Design and methodology of a randomized controlled trial in military veterans","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2018.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}